y11

focal adhesion kinase (FAK) inhibitor

LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator.

BAY1143269 is an orally effective mitogen-activated protein kinase-interacting serine/threonine-protein kinase 1 (MKNK1) inhibitor with potential anti-tumor activity.

BAY1125976 is an allosteric inhibitor of Akt1 and Akt2 (IC50s of 5.2 and 18 nM, respectively, in a time-resolved FRET assay)

[Gly11] Substance P, an analog of Substance P itself, functions as a neuropeptide within the CNS, serving dual roles as both a neurotransmitter and neuromodulator [1].

LY117018 TFA, an analog of Raloxifene, functions as a selective estrogen receptor modulator and demonstrates antiproliferative effects on breast cancer cell lines [1] [2] [3].

BAY 11-7082 (BAY 11-7821) is an NF-κB inhibitor that suppresses TNFα-induced IκBα phosphorylation (IC50=10 μM) and also inhibits the ubiquitin-specific proteases USP7 and USP21 (IC50=0.19/0.96 μM).

Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.

Fluoxetine (LY-110140) is a highly specific serotonin uptake inhibitor and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor. Fluoxetine has antidepressant activity.

Fluoxetine hydrochloride (Lilly110140) is the first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.

Cortisone (17-Hydroxy-11-dehydrocorticosterone) is a corticosteroid with potent glucocorticoid activity.

Indophagolin is a potent, indoline-containing autophagy inhibitor with an IC50 of 140 nM, and it antagonizes the purinergic receptor P2X4 as well as P2X1 and P2X3 with IC50s of 2.71, 2.40, and 3.49 μM, respectively.

GSK-3β inhibitor 10 has skin-whitening, anti-oxidizing and PPAR activities.

(R)-Atuveciclib is an isomer of Atuveciclib. Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb/CDK9 inhibitor with an IC50 value of 13 nm for CDK9/CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages.

Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb/CDK9 inhibitor with an IC50 value of 13 nm for CDK9/CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages.

Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, inhibiting CDK9/CycT1 with an IC50 of 16 nM.

1b-Hydroxy-11a,13-dihydroalantolactone is a useful organic compound for research related to life sciences. The catalog number is T125418 and the CAS number is 200703-30-6.

NF157 significantly decreases the expression of metalloproteinase (MMP)-3, MMP-13, which can be used in the treatment of osteoarthritis (OA). NF157 is a highly selective nanomolar P2Y11 antagonist (pKi: 7.35). The IC50s are 463 nM, 1811 µM, 170 µM for P2Y

Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity.

Bay 11-7085 can irreversibly inhibit the IκBα phosphorylation induced by TNFα (IC50: 10 μM).

Pentomone (LY-113935) is an anti-androgen compound that acts as a prostate growth inhibitor.

KWZY-11 (Compound 11) is a potent dual inhibitor of PARP/CDK6, exhibiting IC50 values of 156.8 nM, 197.3 nM, and 13.3 nM for PARP1, PARP2, and CDK6 respectively. It suppresses tumor cell proliferation by modulating the Wnt/β-catenin signaling pathway. Additionally, KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells.

LY 113174, a novel nonsteroidal aromatase inhibitor, may prove useful in the treatment of estrogen-dependent diseases.

LY 116467 is a dopamine agonist.